Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) reached a new 52-week low on Friday . The stock traded as low as $14.69 and last traded at $14.69, with a volume of 50433 shares traded. The stock had previously closed at $16.19.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on UPB shares. William Blair began coverage on Upstream Bio in a research note on Tuesday, November 5th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $38.00 target price on the stock. Piper Sandler began coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued an “overweight” rating and a $75.00 price objective for the company. Finally, TD Cowen began coverage on Upstream Bio in a research note on Tuesday, November 5th. They issued a “buy” rating for the company.
Get Our Latest Analysis on Upstream Bio
Upstream Bio Stock Performance
Upstream Bio (NASDAQ:UPB – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.83 million. On average, analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current year.
Insider Buying and Selling at Upstream Bio
In other Upstream Bio news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were purchased at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the acquisition, the insider now directly owns 1,175,000 shares in the company, valued at $19,975,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Erez Chimovits acquired 825,000 shares of Upstream Bio stock in a transaction that occurred on Tuesday, October 15th. The stock was acquired at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the acquisition, the director now directly owns 4,554,873 shares in the company, valued at $77,432,841. This represents a 22.12 % increase in their position. The disclosure for this purchase can be found here.
About Upstream Bio
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Upstream Bio
- Industrial Products Stocks Investing
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- About the Markup Calculator
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to Find Undervalued Stocks
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.